Katelyn T. Byrne Medicine University of Pennsylvania, Parker Institute for Cancer Immunotherapy Biography Publications Institution JoVE Articles Katelyn T. ByrneParker Fellow, Instructor in Medicine Katelyn Byrne is a Parker Fellow and Instructor in Medicine in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. She received her undergraduate degree in Biochemistry and Molecular Biology from Boston University, and her Ph.D. in Tumor Immunology from Dartmouth College.Dr. Byrne's training has focused on understanding the interactions between T cells and antigen presenting cells in the context of autoimmunity and tumor immunity. As an undergraduate in Dr. Vicki Rubin Kelley's lab, Dr. Byrne studied the role of colony stimulating factor 1 in mediating nephritis in systemic lupus erythematosus. Her graduate work in Dr. Mary Jo Turk's lab focused on the role of shared tumor/self-antigens in maintaining T cell immunity to melanoma. Dr. Byrne then completed her post-doctoral training with Dr. Robert Vonderheide at the University of Pennsylvania, identifying new therapeutic combinations of agonistic CD40 antibody in a murine model of pancreatic cancer.In 2016, Dr. Byrne was selected as a Parker Fellow from the Parker Institute for Cancer Immunotherapy and transitioned to an Instructor in Medicine at the University of Pennsylvania. Her research program has focused on developing new tools to interrogate immunotherapies in pancreatic cancer, identifying novel treatment combinations, and elucidating the mechanisms by which T cells target and destruct tumor cells in immune-cold tumors. Publications Tumor Cell-intrinsic EPHA2 Suppresses Anti-tumor Immunity by Regulating PTGS2 (COX-2) The Journal of Clinical Investigation. Jun, 2019 | Pubmed ID: 31162144 Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy Immunity. 07, 2018 | Pubmed ID: 29958801 Immunotherapy and Prevention of Pancreatic Cancer Trends in Cancer. 06, 2018 | Pubmed ID: 29860986 Resident Memory T Cells in the Skin Mediate Durable Immunity to Melanoma Science Immunology. Apr, 2017 | Pubmed ID: 28738020 Lack of Immunoediting in Murine Pancreatic Cancer Reversed with Neoantigen JCI Insight. 09, 2016 | Pubmed ID: 27642636 CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer Cell Reports. 06, 2016 | Pubmed ID: 27292635 CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given Before but Not After Chemotherapy Journal of Immunology (Baltimore, Md. : 1950). 07, 2016 | Pubmed ID: 27217585 Special Conference on Tumor Immunology and Immunotherapy: A New Chapter Cancer Immunology Research. 06, 2015 | Pubmed ID: 25968457 Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Cancer Immunology Research. Apr, 2015 | Pubmed ID: 25678581 CD40 Therapy and Surgery: A Potential Immunologic Partnership Journal of Immunotherapy (Hagerstown, Md. : 1997). Sep, 2013 | Pubmed ID: 23924786 मैरिन अग्नाशय के डक्टल एडेनोकार्सिनोमा के अल्ट्रासाउंड-गाइडेड ऑर्थोटोपिक इम्प्लांटेशन Ceire A. Hay1, Rina Sor2,3, Ahron J. Flowers2,3, Cynthia Clendenin2,3, Katelyn T. Byrne1,4 1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 2Pancreatic Cancer Mouse Hospital, Perelman School of Medicine, University of Pennsylvania, 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 4Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania JoVE 60497 Cancer Research
मैरिन अग्नाशय के डक्टल एडेनोकार्सिनोमा के अल्ट्रासाउंड-गाइडेड ऑर्थोटोपिक इम्प्लांटेशन Ceire A. Hay1, Rina Sor2,3, Ahron J. Flowers2,3, Cynthia Clendenin2,3, Katelyn T. Byrne1,4 1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 2Pancreatic Cancer Mouse Hospital, Perelman School of Medicine, University of Pennsylvania, 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 4Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania JoVE 60497 Cancer Research